title: Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver.
abstract: Inhibitors of B cell receptor signaling substantially changed the treatment of chronic lymphocytic leukemia as the first targeted agents to enter routine clinical practice. A recent paper by Roberts and colleagues describes an additional therapeutic target by reporting encouraging clinical results with venetoclax, an inhibitor of the antiapoptotic protein BCL2.
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH 43210, USA.
authors.forename: Kerry A
authors.initials: KA
authors.lastname: Rogers
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH 43210, USA. Electronic address: john.byrd@osumc.edu.
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
mesh_terms: D000814:Aniline Compounds / Q000008:administration & dosage* / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides